Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Paratek Pharma Inc (PRTK)

Paratek Pharma Inc (PRTK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 258,126
  • Shares Outstanding, K 48,795
  • Annual Sales, $ 46,920 K
  • Annual Income, $ -96,540 K
  • 60-Month Beta 1.54
  • Price/Sales 5.08
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PRTK with:

Options Overview Details

View History
  • Implied Volatility 94.22%
  • Historical Volatility 44.63%
  • IV Percentile 57%
  • IV Rank 23.04%
  • IV High 264.19% on 12/07/20
  • IV Low 43.33% on 08/30/21
  • Put/Call Vol Ratio 0.09
  • Today's Volume 1,169
  • Volume Avg (30-Day) 279
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 5,677
  • Open Int (30-Day) 4,364

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.48
  • Number of Estimates 2
  • High Estimate -0.41
  • Low Estimate -0.55
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.61 +14.75%
on 09/14/21
5.71 -7.35%
on 09/01/21
-0.15 (-2.76%)
since 08/24/21
3-Month
4.61 +14.75%
on 09/14/21
7.30 -27.53%
on 06/25/21
-1.94 (-26.83%)
since 06/24/21
52-Week
4.51 +17.29%
on 11/03/20
11.23 -52.91%
on 06/10/21
-0.29 (-5.20%)
since 09/24/20

Most Recent Stories

More News
Paratek Pharmaceuticals Presenting New Data for NUZYRA(R) (omadacycline) at IDWeek 2021

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2021 virtual meeting.

PRTK : 5.29 (+8.18%)
Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 5.29 (+8.18%)
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM

The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.

VRTX : 183.61 (-0.80%)
RGEN : 323.26 (-0.29%)
PRTK : 5.29 (+8.18%)
CRVS : 6.80 (-3.27%)
Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA(R) (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 5.29 (+8.18%)
Paratek Pharmaceuticals (PRTK) Q2 Earnings and Revenues Miss Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -31.03% and -3.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

PRTK : 5.29 (+8.18%)
Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021

-- NUZYRA(R) (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter

PRTK : 5.29 (+8.18%)
Paratek: Q2 Earnings Snapshot

BOSTON (AP) _ Paratek Pharmaceuticals Inc. (PRTK) on Monday reported second-quarter net income of $9.7 million, after reporting a loss in the same period a year earlier.

PRTK : 5.29 (+8.18%)
Acurx Pharmaceuticals Joins the Antimicrobials Working Group

/PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug...

CDTX : 2.24 (-2.61%)
ITRM : 0.5384 (-3.53%)
NBRV : 1.1800 (-2.48%)
PRTK : 5.29 (+8.18%)
SCYX : 5.58 (-0.36%)
SMMT : 5.22 (-2.97%)
ACXP : 4.39 (-7.68%)
Paratek Pharmaceuticals Announces NUZYRA(R) (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 5.29 (+8.18%)
Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases...

PRTK : 5.29 (+8.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use...

See More

Key Turning Points

3rd Resistance Point 6.03
2nd Resistance Point 5.72
1st Resistance Point 5.51
Last Price 5.29
1st Support Level 4.99
2nd Support Level 4.68
3rd Support Level 4.47

See More

52-Week High 11.23
Fibonacci 61.8% 8.67
Fibonacci 50% 7.87
Fibonacci 38.2% 7.08
Last Price 5.29
52-Week Low 4.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar